A cellular immunotherapy company, TrAMPoline Pharma is developing personalized (autologous) therapies for solid tumor cancers. The firm's lead therapeutic candidate - designated MightyTIL™ - is described as a gene engineered tumor infiltrating lymphocyte (TIL) targeting orphan cancer indications (sarcoma, head and neck cancer) and melanoma. Principals of the firm note that this aproach has demonstrated significantly enhanced anti-tumor activity in multiple animal tumor models as compared with conventional unmodified TIL. Noting further that solid tumor cancers make up 90% of all cancers- and that there are currently no FDA approved cellular therapies for solid tumors - the firm's vision is referenced as development of the next generation of cellular immunotherapies soecifically to treat solid tumor cancers. The unmet needs in the treatment of solid tumors are significant. ~60% of cancer patients experience T cell immunotherapy failures -- including checkpoint inhibitors, CAR T cells, TCR-engineered, TIL.
